Form 4: Xencor CEO Bassil Dahiyat Reports Stock Transactions

Bassil Dahiyat, CEO of Xencor, reports the acquisition and disposition of company stock and stock options.

Summary

• On March 5, 2024, Bassil Dahiyat, the President and CEO of Xencor, engaged in transactions involving Xencor's common stock.
• He disposed of 12,528 shares at a price of $23.429 per share to cover withholding taxes related to the vesting of restricted stock units.
• Dahiyat also acquired 54,538 restricted stock units at $0.
• Following these transactions, Dahiyat directly owns 354,635 shares of Xencor common stock.
• Additionally, Dahiyat acquired 327,225 stock options with an exercise price of $22.85, vesting over four years from March 5, 2024.
• Following these transactions, Dahiyat directly owns 327,225 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of standard executive compensation and don't necessarily indicate a strong positive or negative outlook.

Positives

• The acquisition of restricted stock units and stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The sale of shares to cover withholding taxes, while common, could be interpreted negatively by some investors, although it's a standard practice.

Risks

• There are no specific risks explicitly mentioned in this document.
• However, insider transactions are always subject to scrutiny and potential misinterpretation by the market.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the restricted stock units and stock options suggests a multi-year commitment from the CEO.

Industry Context

Insider transactions are common in the biopharmaceutical industry, where stock options and restricted stock units are frequently used as part of executive compensation packages. These transactions are closely monitored by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and vesting schedules are standard practice in the biotech industry, often benchmarked against peer companies like Amgen, Regeneron, and Gilead.
• The vesting schedule of 25% after one year and then monthly thereafter is a typical arrangement to incentivize long-term performance.
• Executive compensation packages, including stock options and RSUs, are often compared against industry surveys and proxy statements of similar-sized companies.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on how they interpret the CEO's actions.
• Employees may view the CEO's stock ownership as a sign of alignment with their interests.

Key Dates